Parabilis Medicines, Inc. (PBLS): Peeking at the IPO Prospectus of a Peptide Therapeutic Company
​Parabilis Medicines set to debut as public biotech company on June 10 with IPO offering 25 million shares in $17-$19 price range, focusing on...
104 Views
Primer: Parabilis Medicines (PBLS US) - Jun 2026
Parabilis Medicines is a clinical-stage biopharmaceutical company pioneering a novel therapeutic modality, Helicon™ peptides, to target...
106 Views